Sign in
NT

NEKTAR THERAPEUTICS (NKTR)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 revenue was $11.8M and diluted EPS was -$1.87; both beat Wall Street consensus (revenue est. ~$10.2M; EPS est. -$2.61) driven by lower operating expenses and stable non-cash royalty revenue; year-over-year revenue declined due to the sale of Huntsville manufacturing (no product sales) [*S&P Global estimates].
  • Management raised year-end cash guidance to ~$240M (from $100M–$185M prior) and extended cash runway into Q2 2027, aided by $107M July secondary and $34.3M September ATM, plus $38.3M in October ATM proceeds .
  • Clinical catalysts strengthened: REZOLVE-AD Phase 2b showed statistically significant asthma comorbidity improvements and validated 24-week induction for planned Phase 3; top-line alopecia areata Phase 2b data expected in December 2025 .
  • Near-term stock reaction catalysts: upcoming AA data, FDA end-of-Phase II meeting for AD, and ACAAI late-breaking AD+asthma data support a differentiated Treg mechanism narrative that may drive estimate revisions and sentiment .

What Went Well and What Went Wrong

What Went Well

  • REZOLVE-AD Phase 2b delivered statistically significant and clinically meaningful improvements across primary and secondary endpoints (EASI, vIGA-AD, NRS-Itch), with late-breaking ACAAI data showing asthma control benefits in AD patients; management highlighted differentiation versus IL‑13/OX‑40 pathways .
  • Operating discipline: total operating expenses fell to $43.5M vs. $58.5M YoY, with R&D down to $27.3M and G&A down to $16.1M, helping EPS beat consensus despite revenue mix shift to non-cash royalties .
  • Liquidity strengthened and runway extended: cash/investments reached $270.2M; year-end cash guided to ~$240M; runway into Q2 2027; CFO reiterated no debt and provided clear FY25 guidance across line items .

Management quote: “We have made tremendous progress advancing rezpegaldesleukin… These compelling data give rezpegaldesleukin a unique position in the competitive landscape… we look forward to reporting in December the topline data for rezpegaldesleukin in… alopecia areata” .

What Went Wrong

  • Year-over-year revenue decline (Q3 2025 $11.8M vs. Q3 2024 $24.1M) due to no product sales post-Huntsville facility divestiture; revenue now primarily non-cash royalty and limited collaboration income .
  • Non-cash equity method losses persisted (Gannet BioChem: $0.5M in Q3; $7.4M YTD), and non-cash interest on royalty liabilities remained elevated ($6.0M in Q3) .
  • Continued net loss (-$35.5M; -$1.87 per share) highlights dependence on clinical milestones and future partnering/approval; the company will enter a quiet period ahead of AA readout, limiting near-term visibility .

Financial Results

MetricQ3 2024Q2 2025Q3 2025
Revenue ($USD Millions)$24.124 $11.175 $11.790
Diluted EPS ($USD)-$2.66 -$2.95 -$1.87
Total Operating Costs & Expenses ($USD Millions)$58.469 $47.405 $43.462
R&D Expense ($USD Millions)$35.031 $29.886 $27.252
G&A Expense ($USD Millions)$18.957 $17.072 $16.070
Net Loss ($USD Millions)$37.057 $41.593 $35.522
Non-GAAP Net Loss ($USD Millions)——$35.0
Non-GAAP EPS ($USD)——-$1.85

Segment Revenue Breakdown

Revenue Component ($USD Millions)Q3 2024Q2 2025Q3 2025
Product Sales$8.015 $0.000 $0.000
Non-cash Royalty Revenue (future royalties)$15.731 $11.175 $11.490
License, Collaboration & Other$0.378 $0.000 $0.300
Total Revenue$24.124 $11.175 $11.790

Margins (S&P Global)

MetricQ3 2024Q2 2025Q3 2025
Net Income Margin %—*—*—*
EBIT Margin %—*—*—*

Values retrieved from S&P Global.*

KPIs

KPIQ3 2024Q2 2025Q3 2025
Cash & Investments ($USD Millions)—$175.9 $270.2
Non-cash Interest Expense ($USD Millions)$6.020 $5.394 $6.047
Equity Method Loss ($USD Millions)$0.000 $2.386 $0.534
Weighted Avg Shares (Basic/Diluted)13,949,851 14,087,307 18,946,559

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Year-end Cash & Investments ($USD Millions)FY 2025$100–$185 ~$240 Raised
Cash RunwayMulti-yearInto Q1 2027 Into Q2 2027 Extended
Non-cash Royalty Revenue ($USD Millions)FY 2025~ $40 ~ $40 Maintained
R&D Expense ($USD Millions)FY 2025$125–$130 $125–$130 Maintained
G&A Expense ($USD Millions)FY 2025$70–$75 $70–$75 Maintained
Non-cash Interest Expense ($USD Millions)FY 2025~ $20 ~ $20 Maintained
Equity Method Loss ($USD Millions)FY 2025~ $10 ~ $10 Maintained

Drivers: Raised year-end cash and extended runway due to July secondary ($107M net), September ATM ($34.3M), and October ATM ($38.3M), plus expense discipline .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q3 2025)Trend
R&D Execution (REZPEG AD)Q1: “On track to report topline AD data in June” ; Q2: AD Phase 2b met primary and key secondary endpoints; 52-week data early 2026 ACAAI late-breaker: statistically significant ACQ‑5 asthma improvements; placebo crossover reinforces 24-week induction; Phase 3 prep ongoing Strengthening clinical dataset
Regulatory/Clinical PathQ1: AD Fast Track; AA enrollment progress ; Q2: AA Fast Track in July End-of-Phase II FDA meeting planned before year-end for AD Advancing toward Phase 3
Financing/LiquidityQ1: runway into Q4 2026 ; Q2: runway into Q1 2027 (pre-July proceeds) Year-end cash ~$240M; runway into Q2 2027; quiet period ahead of AA readout Improved runway
Manufacturing/Supply Chain—Multiple CMO options; pegylation supply priority from facility sold; confident in manufacturing; autoinjector development for launch Building commercial readiness
AA ProgramQ1: Target enrollment completed ; Q2: AA Phase 2b readout guided for Dec Top-line AA results expected Dec; benchmarked to low-dose Olumiant with potential safety advantages Near-term catalyst
NKTR-0165/0166 (TNFR2)Q1: IND-enabling ongoing ; Q2: IND in 2026 goal Progressing; bispecific/trispecific constructs; clinic entry targeted next year Pipeline advancing

Management Commentary

  • CEO (Howard Robin): “These compelling data give rezpegaldesleukin a unique position… Notably, this year’s Nobel Prize… FOXP3-positive Tregs… we look forward to reporting… alopecia areata” .
  • CRDO (Jonathan Zalevsky): “REZPEG’s Treg mechanism differentiates vs IL‑13 and OX‑40; ACAAI data show meaningful ACQ‑5 improvements in uncontrolled asthma subsets” .
  • CFO (Sandra Gardiner): “We now expect to end the year with approximately $240 million… extending our cash runway into the second quarter of 2027” .
  • CMO (Mary Tagliaferri): “We will implement the same procedures to minimize placebo effect in Phase 3… clear path forward to a BLA” .
  • CEO on manufacturing: “Priority position for pegylation materials; multiple CMOs; confident in manufacturing REZPEG” .

Q&A Highlights

  • Asthma comorbidity: Exploratory ACQ‑5 analysis in AD+asthma patients showed clinically significant improvement; management is not pursuing a standalone asthma indication but sees differentiation for AD with comorbidity .
  • Alopecia strategy: Benchmarked to low-dose Olumiant; opportunity even at modest efficacy given safety profile and absence of JAK black box warnings; Phase 3 could start next year if data are positive .
  • Trial design: AD Phase 3 will apply rigorous procedures to minimize placebo effects; crossover and subgroup consistency strengthen Phase 3 readiness .
  • CMC and device: Autoinjector development ongoing, targeted for launch; Phase 3 to proceed with vials for speed; comprehensive CMC/BLA plan discussed with FDA .
  • Manufacturing footprint: Pegylation capability secured via priority access; multiple CMOs engaged; no current manufacturing constraints flagged .

Estimates Context

MetricQ1 2025Q2 2025Q3 2025
Revenue Consensus Mean ($USD)$15.355M*$9.416M*$10.197M*
Revenue Actual ($USD)$10.460M*$11.175M*$11.790M*
Primary EPS Consensus Mean ($USD)-$2.496*-$3.034*-$2.607*
Primary EPS Actual ($USD)-$3.606*-$2.780*-$1.868*

Values retrieved from S&P Global.*

Comparison takeaways:

  • Q3: Revenue and EPS both were beats vs consensus; revenue beat by ~$1.6M; EPS beat by ~$0.74; driven by lower operating spend and stable royalty revenue; bold beat implications for near-term sentiment. Beat [*S&P Global estimates] .
  • Q2: Both revenue and EPS exceeded consensus; execution and expense control improved vs Q1 [*S&P Global estimates] .
  • Q1: Misses on S&P-normalized EPS and revenue as the portfolio transitioned post-Huntsville sale; note per-share figures in Q1 press release were pre-reverse-split and not directly comparable [*S&P Global estimates] .

Key Takeaways for Investors

  • Near-term catalyst density is high: top-line AA Phase 2b data in December and an FDA end-of-Phase II meeting for AD can re-rate probability of success and drive estimate revisions .
  • Differentiation in AD strengthened by asthma comorbidity improvements (ACQ‑5) and consistency across subgroups; supports a 24-week induction and Phase 3 dose selection, a potential commercial edge vs IL‑13/OX‑40 programs .
  • Liquidity enhanced and runway extended into Q2 2027 via July secondary and ATM activity; reduces financing overhang pre-Phase 3 initiation and AA expansion .
  • Expense discipline is evident (R&D and G&A down YoY), enabling EPS beats at low revenue levels; sustained opex control is key as Phase 3 costs ramp in 2026 .
  • In AA, a favorable safety profile without JAK black box warnings could unlock share even at moderate efficacy; physician comfort and durability (off-drug hair maintenance) are strategic levers .
  • Manufacturing and device readiness progressing (CMO network, autoinjector for launch), de-risking CMC as pivotal programs approach; watch for further CMC updates post-FDA meeting .
  • Trading stance: Q4 headline risk skewed positive (AA readout), with potential for multiple expansion on efficacy and safety signals; a December quiet period limits interim disclosures, so positioning ahead of readout may be rewarded if data align with benchmarks .

Notes and Disclosures

  • The company reported that revenue decreased year-over-year due to the sale of its Huntsville manufacturing facility in December 2024 (no product sales recognized) .
  • Non-GAAP results exclude non-cash equity method losses (Gannet BioChem: $0.5M in Q3; $7.4M YTD); non-GAAP net loss and EPS were $35.0M and -$1.85, respectively .
  • Guidance items (non-cash royalty revenue, R&D, G&A, non-cash interest, equity method loss) were maintained; cash guidance was raised and runway extended .
  • Per-share amounts in Q3/Q2 reflect the one-for-fifteen reverse stock split completed on June 8, 2025; Q3 press materials state retrospective adjustment, while Q1 per-share figures were pre-split and not directly comparable .